Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury

Journal of Pineal Research

Volumn 33, Issue 3, 2002, Pages 161-166

  Parlakpinar, Hakan ^a   Sahna, Engin ^a   Ozer, M K ^a   Ozugurlu, Fikret ^a   Vardi, Nigar ^a   Acet, Ahmet ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Malondialdehyde; Melatonin; Pinealectomy; Rat; Renal injury

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE; MALONALDEHYDE; MELATONIN;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID PEROXIDATION; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PINEAL BODY; PINEALECTOMY; RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CISPLATIN; FEMALE; FREE RADICAL SCAVENGERS; KIDNEY; MALONDIALDEHYDE; MELATONIN; RATS; RATS, WISTAR;

EID: 0036786265     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2002.02910.x     Document Type: Article

References (32)

1. MUGGIA FM. Cisplatin update. Semin Oncol 1991; 18:1-4.
2. YANG DZ, WANG AHJ. Structural studies of interactions between anticancer platinum drugs and DNA. Prog Biophys Mol Biol 1997; 66:81-111.
3. WINSTON JA, SAFIRSTEIN R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985; 249:490-496.
4. WATANABE H, KANNO H. Experimental studies of the effect of deferoxamine mesilate on cisplatin induced toxicity. Nippon Jibiinkoka Gakkai Kaiho 1998; 101:967-978.
5. BALIGA R, ZHANG Z, BALIGA M et al. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998; 53:394-401.
6. RAO M, KUMAR MM, RAO MA. In vitro and in vivo effects of phenolic antioxidants against cisplatin-induced nephrotoxicity. J Biochem 1999; 125:383-390.
7. OZBEK E, CEKMEN M, TURKOZ Y. The effects of cuffeic acid phenethyl ester on cisplatin nephrotoxicity increased antioxidant enzyme activity in kidney. Int Med J 2000; 7:129-131.
8. APPENROTH D, FRÖB S, KERSTEN L et al. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 1997; 71:677-683.
9. SENER G, SATIROGLU H, KABASAKAL L et al. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam Clin Pharmacol 2000; 14:553-560.
10. SEWERYNEK E, ABE M, REITER RJ et al. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals. J Cell Biochem 1995; 58:436-444.
11. REITER RJ, MELCHIORRI D, SEWERYNEK E et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995; 18:1-11.
12. REITER RJ, GUERRERO JM, GARCIA JJ et al. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann NY Acad Sci 1998; 854:410-424.
13. PIERREFICHE G, TOPALL G, COURBOYN G et al. Antioxidant activity of melatonin in mice. Res Commun Chem Pathol Pharmacol 1993; 80:211-223.
14. KUSZAK J, RODIN M. A new technique of pinealectomy for adult rats. Experientia 1977; 33:283-284.
15. VERMEULEN NPE, BALDEW GS. The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol 1992; 44:1193-1199.
16. LAU AH. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 1999; 56:1295-1298.
17. ZUNINO F, PRATESI G, MICHELONI A et al. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 1989; 70:89-101.
18. WALKER EM, GALE GR. Methods of reduction of cisplatin nephrotoxicity. Ann Clin Lab Sci 1981; 11:397-410.
19. BABU E, GOPALAKRISHNAN VK, SRIGANTH IN et al. Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 1995; 144:7-11.
20. REITER RJ, TAN DX, LUCIEN CM et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochem Biophys 2001; 34:237-256.
21. TAN DX, REITER RJ, MANCHESTER LC et al. Chemical and physical properties and potential mechanism: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-197.
22. REITER J. Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Front Neuroendocrinol 1995; 16:383-415.
23. TAN D, CHEN LD, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
24. AGAPlTO MT, ANTOLIN Y, DEL BRIO MT et al. Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res 2001; 31:23-30.
25. HARA M, YOSHIDA M, NISHIJIMA H et al. Melatonin, a pineal secretory product with antioxidant properties. protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001; 30:129-138.
26. VAUGHAN GM, REITER RJ. Pineal dependence of the Syrian hamster's nocturnal serum melatonin surge. J Pineal Res 1986; 3:9-14.
27. ZANOBONI A, FORNI A, ZANOBONI-MUCIACCIA W et al. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J Endocrinol Invest 1978; 1:125-130.
28. HANNEMANN J, BAUMANN K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 1988; 51:119-132.
29. MONTILLA P, TUNEZ I, MUNOZ MC et al. Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron 1997; 76:345-350.
30. OZBEK E, TURKOZ Y, SAHNA E et al. Melatonin administration prevents the nephrotoxicity induced by gentamycin. BJU Int 2000; 85:742-746.
31. ACUNA-CASTROVIEJO D, MARTIN M, MACIAS M et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30:65-74.
32. REITER RJ, TAN DX, SAINZ RM et al. Melatonin protects the heart against both ischemia/reperfusion injury and chemotherapeutic drugs. Cardiovasc Drugs Ther 2002; 16:5-6.